Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFIZER, INC
+0.36 (1.05%)
Real-time:   11:33AM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 34.06 - 34.76
52 week 27.51 - 34.97
Open 34.06
Vol / Avg. 8.18M/31.92M
Mkt cap 216.05B
P/E 24.47
Div/yield 0.28/3.23
EPS 1.42
Shares 6.30B
Beta 0.69
Inst. own 72%
May 4, 2015
Q1 2015 Pfizer Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 3, 2015
Pfizer Inc at Cowen Health Care Conference - 10:00AM EST - Add to calendar
Feb 10, 2015
Pfizer Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 5, 2015
Pfizer Inc Discussing Proposed Acquisition of Hospira Call (Media)
Feb 5, 2015
Pfizer Inc Discussing Proposed Acquisition of Hospira Call (Analyst and Investor)
Jan 27, 2015
Q4 2014 Pfizer Inc Earnings Call
Jan 27, 2015
Q4 2014 Pfizer Inc Earnings Release
Jan 13, 2015
Pfizer Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 9.59% 18.39%
Operating margin 15.35% 25.98%
EBITD margin - 38.02%
Return on average assets - -
Return on average equity - -
Employees 77,700 -
CDP Score - 92 B


235 E 42ND ST
NEW YORK, NY 10017
United States - Map
+1-212-5732323 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company�s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. Primary Care operating segment includes revenues from human prescription pharmaceutical products primarily prescribed by primary-care physicians. In November 2012, the Company acquired NextWave Pharmaceuticals, Inc. On November 30, 2012, the Company completed the sale of its Nutrition business.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 56
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 52
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 55
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 53
Bio & Compensation  - Reuters
John D. Young Group President - Global Established Pharma Business
Age: 49
Bio & Compensation  - Reuters
Rady A. Johnson Executive Vice President, Chief Compliance and Risk Officer
Age: 52
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 58
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters